APO Research
Talk to an analyst

APO RESEARCH · REPORT

Non-Invasive Prenatal Screening (NIPS)

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Non-Invasive Prenatal Screening (NIPS) Market Analysis and Forecast 2026-2032

12 April 2026205 pages

Choose your research edition.

Industry ResearchNon-Invasive Prenatal Screening (NIPS) Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Non-Invasive Prenatal Screening (NIPS) Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Non-Invasive Prenatal Screening (NIPS) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Non-Invasive Prenatal Screening (NIPS) Market Outlook and Growth Opportunities 2026$4,250 USDMarket Analysis & ForecastGlobal Non-Invasive Prenatal Screening (NIPS) Market Analysis and Forecast 2026-2032205 pages · $4,950 USD

Market perspective

The global Non-Invasive Prenatal Screening (NIPS) market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Non-Invasive Prenatal Screening (NIPS) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Non-Invasive Prenatal Screening (NIPS) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Non-Invasive Prenatal Screening (NIPS) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Non-Invasive Prenatal Screening (NIPS) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Non-Invasive Prenatal Screening (NIPS) include Revvity, Quest Diagnostics, MedGenome, Mayo Clinic Laboratories, SYNLAB, Veritas Genetics, GGA, Cordlife and BGI Genomics, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Non-Invasive Prenatal Screening (NIPS), market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Non-Invasive Prenatal Screening (NIPS), also provides the revenue of main regions and countries. Of the upcoming market potential for Non-Invasive Prenatal Screening (NIPS), and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Non-Invasive Prenatal Screening (NIPS) revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Non-Invasive Prenatal Screening (NIPS) market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Non-Invasive Prenatal Screening (NIPS) revenue, projected growth trends, production technology, application and end-user industry.

Non-Invasive Prenatal Screening (NIPS) Segment by Company

Revvity

Quest Diagnostics

MedGenome

Mayo Clinic Laboratories

SYNLAB

Veritas Genetics

GGA

Cordlife

BGI Genomics

Berry Genomics

Annaroad

Genesky

Weihansi Biomedical Technology

Non-Invasive Prenatal Screening (NIPS) Segment by Type

Screening in Uncomplicated Pregnancies

Screening in High-Risk Pregnancies

Others

Non-Invasive Prenatal Screening (NIPS) Segment by Application

Public Hospitals

Private Hospitals

Non-Invasive Prenatal Screening (NIPS) Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Non-Invasive Prenatal Screening (NIPS) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Non-Invasive Prenatal Screening (NIPS) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Non-Invasive Prenatal Screening (NIPS).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Non-Invasive Prenatal Screening (NIPS) in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Non-Invasive Prenatal Screening (NIPS) company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Non-Invasive Prenatal Screening (NIPS) revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Non-Invasive Prenatal Screening (NIPS) Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Screening in Uncomplicated Pregnancies Major Player Table 3. Screening in High-Risk Pregnancies Major Player Table 4. Others Major Player Table 5. Global Non-Invasive Prenatal Screening (NIPS) Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Public Hospitals Major Player Table 7. Private Hospitals Major Player Table 8. Non-Invasive Prenatal Screening (NIPS) Industry Trends Table 9. Non-Invasive Prenatal Screening (NIPS) Industry Drivers Table 10. Non-Invasive Prenatal Screening (NIPS) Industry Opportunities and Challenges Table 11. Non-Invasive Prenatal Screening (NIPS) Industry Restraints Table 12. Global Non-Invasive Prenatal Screening (NIPS) Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 13. Global Non-Invasive Prenatal Screening (NIPS) Market Size by Region (2021-2026) & (US$ Million) Table 14. Global Non-Invasive Prenatal Screening (NIPS) Market Share by Region (2021-2026) Table 15. Global Non-Invasive Prenatal Screening (NIPS) Market Size by Region (2027-2032) & (US$ Million) Table 16. Global Non-Invasive Prenatal Screening (NIPS) Market Share by Region (2027-2032) Table 17. Global Non-Invasive Prenatal Screening (NIPS) Revenue by Players (US$ Million) & (2021-2026) Table 18. Global Non-Invasive Prenatal Screening (NIPS) Revenue Market Share by Players (2021-2026) Table 19. Global Non-Invasive Prenatal Screening (NIPS) Key Players Ranking, 2024 VS 2025 VS 2026 Table 20. Global Non-Invasive Prenatal Screening (NIPS) Key Players Headquarters & Area Served Table 21. Global Non-Invasive Prenatal Screening (NIPS) Players, Product Type & Application Table 22. Global Non-Invasive Prenatal Screening (NIPS) Players Establishment Date Table 23. Global Players Market Concentration Ratio (CR5 and HHI) Table 24. Global Non-Invasive Prenatal Screening (NIPS) by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 25. Global Non-Invasive Prenatal Screening (NIPS) Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Non-Invasive Prenatal Screening (NIPS) Revenue by Type (2021-2026) & (US$ Million) Table 27. Global Non-Invasive Prenatal Screening (NIPS) Revenue by Type (2027-2032) & (US$ Million) Table 28. Global Non-Invasive Prenatal Screening (NIPS) Revenue Market Share by Type (2021-2026) Table 29. Global Non-Invasive Prenatal Screening (NIPS) Revenue Market Share by Type (2027-2032) Table 30. Global Non-Invasive Prenatal Screening (NIPS) Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Non-Invasive Prenatal Screening (NIPS) Revenue by Application (2021-2026) & (US$ Million) Table 32. Global Non-Invasive Prenatal Screening (NIPS) Revenue by Application (2027-2032) & (US$ Million) Table 33. Global Non-Invasive Prenatal Screening (NIPS) Revenue Market Share by Application (2021-2026) Table 34. Global Non-Invasive Prenatal Screening (NIPS) Revenue Market Share by Application (2027-2032) Table 35. Revvity Company Information Table 36. Revvity Business Overview Table 37. Revvity Non-Invasive Prenatal Screening (NIPS) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. Revvity Non-Invasive Prenatal Screening (NIPS) Product Portfolio Table 39. Revvity Recent Development Table 40. Quest Diagnostics Company Information Table 41. Quest Diagnostics Business Overview Table 42. Quest Diagnostics Non-Invasive Prenatal Screening (NIPS) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Quest Diagnostics Non-Invasive Prenatal Screening (NIPS) Product Portfolio Table 44. Quest Diagnostics Recent Development Table 45. MedGenome Company Information Table 46. MedGenome Business Overview Table 47. MedGenome Non-Invasive Prenatal Screening (NIPS) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. MedGenome Non-Invasive Prenatal Screening (NIPS) Product Portfolio Table 49. MedGenome Recent Development Table 50. Mayo Clinic Laboratories Company Information Table 51. Mayo Clinic Laboratories Business Overview Table 52. Mayo Clinic Laboratories Non-Invasive Prenatal Screening (NIPS) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Mayo Clinic Laboratories Non-Invasive Prenatal Screening (NIPS) Product Portfolio Table 54. Mayo Clinic Laboratories Recent Development Table 55. SYNLAB Company Information Table 56. SYNLAB Business Overview Table 57. SYNLAB Non-Invasive Prenatal Screening (NIPS) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. SYNLAB Non-Invasive Prenatal Screening (NIPS) Product Portfolio Table 59. SYNLAB Recent Development Table 60. Veritas Genetics Company Information Table 61. Veritas Genetics Business Overview Table 62. Veritas Genetics Non-Invasive Prenatal Screening (NIPS) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. Veritas Genetics Non-Invasive Prenatal Screening (NIPS) Product Portfolio Table 64. Veritas Genetics Recent Development Table 65. GGA Company Information Table 66. GGA Business Overview Table 67. GGA Non-Invasive Prenatal Screening (NIPS) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. GGA Non-Invasive Prenatal Screening (NIPS) Product Portfolio Table 69. GGA Recent Development Table 70. Cordlife Company Information Table 71. Cordlife Business Overview Table 72. Cordlife Non-Invasive Prenatal Screening (NIPS) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 73. Cordlife Non-Invasive Prenatal Screening (NIPS) Product Portfolio Table 74. Cordlife Recent Development Table 75. BGI Genomics Company Information Table 76. BGI Genomics Business Overview Table 77. BGI Genomics Non-Invasive Prenatal Screening (NIPS) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 78. BGI Genomics Non-Invasive Prenatal Screening (NIPS) Product Portfolio Table 79. BGI Genomics Recent Development Table 80. Berry Genomics Company Information Table 81. Berry Genomics Business Overview Table 82. Berry Genomics Non-Invasive Prenatal Screening (NIPS) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 83. Berry Genomics Non-Invasive Prenatal Screening (NIPS) Product Portfolio Table 84. Berry Genomics Recent Development Table 85. Annaroad Company Information Table 86. Annaroad Business Overview Table 87. Annaroad Non-Invasive Prenatal Screening (NIPS) Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 88. Annaroad Non-Invasive Prenatal Screening (NIPS) Product Portfolio Table 89. Annaroad Recent Development Table 90. Genesky Company Information Table 91. Genesky Business Overview Table 92. Genesky Non-Invasive Prenatal Screening (NIPS) Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 93. Genesky Non-Invasive Prenatal Screening (NIPS) Product Portfolio Table 94. Genesky Recent Development Table 95. Weihansi Biomedical Technology Company Information Table 96. Weihansi Biomedical Technology Business Overview Table 97. Weihansi Biomedical Technology Non-Invasive Prenatal Screening (NIPS) Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 98. Weihansi Biomedical Technology Non-Invasive Prenatal Screening (NIPS) Product Portfolio Table 99. Weihansi Biomedical Technology Recent Development Table 100. North America Non-Invasive Prenatal Screening (NIPS) Revenue by Type (2021-2026) & (US$ Million) Table 101. North America Non-Invasive Prenatal Screening (NIPS) Revenue by Type (2027-2032) & (US$ Million) Table 102. North America Non-Invasive Prenatal Screening (NIPS) Revenue by Application (2021-2026) & (US$ Million) Table 103. North America Non-Invasive Prenatal Screening (NIPS) Revenue by Application (2027-2032) & (US$ Million) Table 104. North America Non-Invasive Prenatal Screening (NIPS) Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 105. North America Non-Invasive Prenatal Screening (NIPS) Revenue by Country (2021-2026) & (US$ Million) Table 106. North America Non-Invasive Prenatal Screening (NIPS) Revenue by Country (US$ Million) & (2027-2032) Table 107. Europe Non-Invasive Prenatal Screening (NIPS) Revenue by Type (2021-2026) & (US$ Million) Table 108. Europe Non-Invasive Prenatal Screening (NIPS) Revenue by Type (2027-2032) & (US$ Million) Table 109. Europe Non-Invasive Prenatal Screening (NIPS) Revenue by Application (2021-2026) & (US$ Million) Table 110. Europe Non-Invasive Prenatal Screening (NIPS) Revenue by Application (2027-2032) & (US$ Million) Table 111. Europe Non-Invasive Prenatal Screening (NIPS) Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 112. Europe Non-Invasive Prenatal Screening (NIPS) Revenue by Country (2021-2026) & (US$ Million) Table 113. Europe Non-Invasive Prenatal Screening (NIPS) Revenue by Country (US$ Million) & (2027-2032) Table 114. China Non-Invasive Prenatal Screening (NIPS) Revenue by Type (2021-2026) & (US$ Million) Table 115. China Non-Invasive Prenatal Screening (NIPS) Revenue by Type (2027-2032) & (US$ Million) Table 116. China Non-Invasive Prenatal Screening (NIPS) Revenue by Application (2021-2026) & (US$ Million) Table 117. China Non-Invasive Prenatal Screening (NIPS) Revenue by Application (2027-2032) & (US$ Million) Table 118. Asia Non-Invasive Prenatal Screening (NIPS) Revenue by Type (2021-2026) & (US$ Million) Table 119. Asia Non-Invasive Prenatal Screening (NIPS) Revenue by Type (2027-2032) & (US$ Million) Table 120. Asia Non-Invasive Prenatal Screening (NIPS) Revenue by Application (2021-2026) & (US$ Million) Table 121. Asia Non-Invasive Prenatal Screening (NIPS) Revenue by Application (2027-2032) & (US$ Million) Table 122. Asia Non-Invasive Prenatal Screening (NIPS) Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 123. Asia Non-Invasive Prenatal Screening (NIPS) Revenue by Region (US$ Million) & (2021-2026) Table 124. Asia Non-Invasive Prenatal Screening (NIPS) Revenue by Region (US$ Million) & (2027-2032) Table 125. SAMEA Non-Invasive Prenatal Screening (NIPS) Revenue by Type (2021-2026) & (US$ Million) Table 126. SAMEA Non-Invasive Prenatal Screening (NIPS) Revenue by Type (2027-2032) & (US$ Million) Table 127. SAMEA Non-Invasive Prenatal Screening (NIPS) Revenue by Application (2021-2026) & (US$ Million) Table 128. SAMEA Non-Invasive Prenatal Screening (NIPS) Revenue by Application (2027-2032) & (US$ Million) Table 129. SAMEA Non-Invasive Prenatal Screening (NIPS) Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 130. SAMEA Non-Invasive Prenatal Screening (NIPS) Revenue by Country (2021-2026) & (US$ Million) Table 131. SAMEA Non-Invasive Prenatal Screening (NIPS) Revenue by Country (US$ Million) & (2027-2032) Table 132. Research Programs/Design for This Report Table 133. Authors List of This Report Table 134. Secondary Sources Table 135. Primary Sources List of Figures Figure 1. Non-Invasive Prenatal Screening (NIPS) Image Figure 2. Global Non-Invasive Prenatal Screening (NIPS) Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Non-Invasive Prenatal Screening (NIPS) Market Size Share 2021 VS 2025 VS 2032 Figure 4. Screening in Uncomplicated Pregnancies Image Figure 5. Screening in High-Risk Pregnancies Image Figure 6. Others Image Figure 7. Global Non-Invasive Prenatal Screening (NIPS) Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Non-Invasive Prenatal Screening (NIPS) Market Size Share 2021 VS 2025 VS 2032 Figure 9. Public Hospitals Image Figure 10. Private Hospitals Image Figure 11. Global Non-Invasive Prenatal Screening (NIPS) Market Size (US$ Million) & (2021-2032) Figure 12. Global Non-Invasive Prenatal Screening (NIPS) Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Non-Invasive Prenatal Screening (NIPS) Market Share by Region: 2021 VS 2025 VS 2032 Figure 14. Global Non-Invasive Prenatal Screening (NIPS) Players Revenue Share Top 10 and Top 5 in 2025 Figure 15. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 16. Global Non-Invasive Prenatal Screening (NIPS) Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Non-Invasive Prenatal Screening (NIPS) Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Non-Invasive Prenatal Screening (NIPS) Revenue Market Share by Type (2021-2032) Figure 19. Global Non-Invasive Prenatal Screening (NIPS) Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Non-Invasive Prenatal Screening (NIPS) Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 21. Global Non-Invasive Prenatal Screening (NIPS) Revenue Market Share by Application (2021-2032) Figure 22. North America Non-Invasive Prenatal Screening (NIPS) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 23. North America Non-Invasive Prenatal Screening (NIPS) Revenue Share by Type (2021-2032) Figure 24. North America Non-Invasive Prenatal Screening (NIPS) Revenue Share by Application (2021-2032) Figure 25. North America Non-Invasive Prenatal Screening (NIPS) Revenue Share by Country (2021-2032) Figure 26. United States Non-Invasive Prenatal Screening (NIPS) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Canada Non-Invasive Prenatal Screening (NIPS) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Mexico Non-Invasive Prenatal Screening (NIPS) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Europe Non-Invasive Prenatal Screening (NIPS) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 30. Europe Non-Invasive Prenatal Screening (NIPS) Revenue Share by Type (2021-2032) Figure 31. Europe Non-Invasive Prenatal Screening (NIPS) Revenue Share by Application (2021-2032) Figure 32. Europe Non-Invasive Prenatal Screening (NIPS) Revenue Share by Country (2021-2032) Figure 33. Germany Non-Invasive Prenatal Screening (NIPS) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. France Non-Invasive Prenatal Screening (NIPS) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. U.K. Non-Invasive Prenatal Screening (NIPS) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Italy Non-Invasive Prenatal Screening (NIPS) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Spain Non-Invasive Prenatal Screening (NIPS) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Russia Non-Invasive Prenatal Screening (NIPS) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Netherlands Non-Invasive Prenatal Screening (NIPS) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Nordic Countries Non-Invasive Prenatal Screening (NIPS) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. China Non-Invasive Prenatal Screening (NIPS) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 42. China Non-Invasive Prenatal Screening (NIPS) Revenue Share by Type (2021-2032) Figure 43. China Non-Invasive Prenatal Screening (NIPS) Revenue Share by Application (2021-2032) Figure 44. Asia Non-Invasive Prenatal Screening (NIPS) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. Asia Non-Invasive Prenatal Screening (NIPS) Revenue Share by Type (2021-2032) Figure 46. Asia Non-Invasive Prenatal Screening (NIPS) Revenue Share by Application (2021-2032) Figure 47. Asia Non-Invasive Prenatal Screening (NIPS) Revenue Share by Region (2021-2032) Figure 48. Japan Non-Invasive Prenatal Screening (NIPS) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. South Korea Non-Invasive Prenatal Screening (NIPS) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. India Non-Invasive Prenatal Screening (NIPS) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Australia Non-Invasive Prenatal Screening (NIPS) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Taiwan Non-Invasive Prenatal Screening (NIPS) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Southeast Asia Non-Invasive Prenatal Screening (NIPS) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. SAMEA Non-Invasive Prenatal Screening (NIPS) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 55. SAMEA Non-Invasive Prenatal Screening (NIPS) Revenue Share by Type (2021-2032) Figure 56. SAMEA Non-Invasive Prenatal Screening (NIPS) Revenue Share by Application (2021-2032) Figure 57. SAMEA Non-Invasive Prenatal Screening (NIPS) Revenue Share by Country (2021-2032) Figure 58. Brazil Non-Invasive Prenatal Screening (NIPS) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Argentina Non-Invasive Prenatal Screening (NIPS) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Chile Non-Invasive Prenatal Screening (NIPS) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Colombia Non-Invasive Prenatal Screening (NIPS) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Peru Non-Invasive Prenatal Screening (NIPS) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Saudi Arabia Non-Invasive Prenatal Screening (NIPS) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Israel Non-Invasive Prenatal Screening (NIPS) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. UAE Non-Invasive Prenatal Screening (NIPS) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Turkey Non-Invasive Prenatal Screening (NIPS) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Iran Non-Invasive Prenatal Screening (NIPS) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Egypt Non-Invasive Prenatal Screening (NIPS) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Screening in Uncomplicated Pregnancies
  • Screening in High-Risk Pregnancies
  • Others
Applications
  • Public Hospitals
  • Private Hospitals
Companies covered
  • Revvity
  • Quest Diagnostics
  • MedGenome
  • Mayo Clinic Laboratories
  • SYNLAB
  • Veritas Genetics
  • GGA
  • Cordlife
  • BGI Genomics
  • Berry Genomics
  • Annaroad
  • Genesky
  • Weihansi Biomedical Technology

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Non-Invasive Prenatal Screening (NIPS) Market by Type
  3. 1.2.1 Global Non-Invasive Prenatal Screening (NIPS) Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Screening in Uncomplicated Pregnancies
  5. 1.2.3 Screening in High-Risk Pregnancies
  6. 1.2.4 Others
  7. 1.3 Non-Invasive Prenatal Screening (NIPS) Market by Application
  8. 1.3.1 Global Non-Invasive Prenatal Screening (NIPS) Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Public Hospitals
  10. 1.3.3 Private Hospitals
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Non-Invasive Prenatal Screening (NIPS) Market Dynamics
  1. 2.1 Non-Invasive Prenatal Screening (NIPS) Industry Trends
  2. 2.2 Non-Invasive Prenatal Screening (NIPS) Industry Drivers
  3. 2.3 Non-Invasive Prenatal Screening (NIPS) Industry Opportunities and Challenges
  4. 2.4 Non-Invasive Prenatal Screening (NIPS) Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Non-Invasive Prenatal Screening (NIPS) Market Perspective (2021-2032)
  2. 3.2 Global Non-Invasive Prenatal Screening (NIPS) Growth Trends by Region
  3. 3.2.1 Global Non-Invasive Prenatal Screening (NIPS) Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Non-Invasive Prenatal Screening (NIPS) Market Size by Region (2021-2026)
  5. 3.2.3 Global Non-Invasive Prenatal Screening (NIPS) Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Non-Invasive Prenatal Screening (NIPS) Revenue by Players
  2. 4.1.1 Global Non-Invasive Prenatal Screening (NIPS) Revenue by Players (2021-2026)
  3. 4.1.2 Global Non-Invasive Prenatal Screening (NIPS) Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Non-Invasive Prenatal Screening (NIPS) Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Non-Invasive Prenatal Screening (NIPS) Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Non-Invasive Prenatal Screening (NIPS) Key Players Headquarters & Area Served
  7. 4.4 Global Non-Invasive Prenatal Screening (NIPS) Players, Product Type & Application
  8. 4.5 Global Non-Invasive Prenatal Screening (NIPS) Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Non-Invasive Prenatal Screening (NIPS) Market CR5 and HHI
  11. 4.6.3 2025 Non-Invasive Prenatal Screening (NIPS) Tier 1, Tier 2, and Tier 3
5 Non-Invasive Prenatal Screening (NIPS) Market Size by Type
  1. 5.1 Global Non-Invasive Prenatal Screening (NIPS) Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Non-Invasive Prenatal Screening (NIPS) Revenue by Type (2021-2032)
  3. 5.3 Global Non-Invasive Prenatal Screening (NIPS) Revenue Market Share by Type (2021-2032)
6 Non-Invasive Prenatal Screening (NIPS) Market Size by Application
  1. 6.1 Global Non-Invasive Prenatal Screening (NIPS) Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Non-Invasive Prenatal Screening (NIPS) Revenue by Application (2021-2032)
  3. 6.3 Global Non-Invasive Prenatal Screening (NIPS) Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Revvity
  2. 7.1.1 Revvity Company Information
  3. 7.1.2 Revvity Business Overview
  4. 7.1.3 Revvity Non-Invasive Prenatal Screening (NIPS) Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Revvity Non-Invasive Prenatal Screening (NIPS) Product Portfolio
  6. 7.1.5 Revvity Recent Developments
  7. 7.2 Quest Diagnostics
  8. 7.2.1 Quest Diagnostics Company Information
  9. 7.2.2 Quest Diagnostics Business Overview
  10. 7.2.3 Quest Diagnostics Non-Invasive Prenatal Screening (NIPS) Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Quest Diagnostics Non-Invasive Prenatal Screening (NIPS) Product Portfolio
  12. 7.2.5 Quest Diagnostics Recent Developments
  13. 7.3 MedGenome
  14. 7.3.1 MedGenome Company Information
  15. 7.3.2 MedGenome Business Overview
  16. 7.3.3 MedGenome Non-Invasive Prenatal Screening (NIPS) Revenue and Gross Margin (2021-2026)
  17. 7.3.4 MedGenome Non-Invasive Prenatal Screening (NIPS) Product Portfolio
  18. 7.3.5 MedGenome Recent Developments
  19. 7.4 Mayo Clinic Laboratories
  20. 7.4.1 Mayo Clinic Laboratories Company Information
  21. 7.4.2 Mayo Clinic Laboratories Business Overview
  22. 7.4.3 Mayo Clinic Laboratories Non-Invasive Prenatal Screening (NIPS) Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Mayo Clinic Laboratories Non-Invasive Prenatal Screening (NIPS) Product Portfolio
  24. 7.4.5 Mayo Clinic Laboratories Recent Developments
  25. 7.5 SYNLAB
  26. 7.5.1 SYNLAB Company Information
  27. 7.5.2 SYNLAB Business Overview
  28. 7.5.3 SYNLAB Non-Invasive Prenatal Screening (NIPS) Revenue and Gross Margin (2021-2026)
  29. 7.5.4 SYNLAB Non-Invasive Prenatal Screening (NIPS) Product Portfolio
  30. 7.5.5 SYNLAB Recent Developments
  31. 7.6 Veritas Genetics
  32. 7.6.1 Veritas Genetics Company Information
  33. 7.6.2 Veritas Genetics Business Overview
  34. 7.6.3 Veritas Genetics Non-Invasive Prenatal Screening (NIPS) Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Veritas Genetics Non-Invasive Prenatal Screening (NIPS) Product Portfolio
  36. 7.6.5 Veritas Genetics Recent Developments
  37. 7.7 GGA
  38. 7.7.1 GGA Company Information
  39. 7.7.2 GGA Business Overview
  40. 7.7.3 GGA Non-Invasive Prenatal Screening (NIPS) Revenue and Gross Margin (2021-2026)
  41. 7.7.4 GGA Non-Invasive Prenatal Screening (NIPS) Product Portfolio
  42. 7.7.5 GGA Recent Developments
  43. 7.8 Cordlife
  44. 7.8.1 Cordlife Company Information
  45. 7.8.2 Cordlife Business Overview
  46. 7.8.3 Cordlife Non-Invasive Prenatal Screening (NIPS) Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Cordlife Non-Invasive Prenatal Screening (NIPS) Product Portfolio
  48. 7.8.5 Cordlife Recent Developments
  49. 7.9 BGI Genomics
  50. 7.9.1 BGI Genomics Company Information
  51. 7.9.2 BGI Genomics Business Overview
  52. 7.9.3 BGI Genomics Non-Invasive Prenatal Screening (NIPS) Revenue and Gross Margin (2021-2026)
  53. 7.9.4 BGI Genomics Non-Invasive Prenatal Screening (NIPS) Product Portfolio
  54. 7.9.5 BGI Genomics Recent Developments
  55. 7.10 Berry Genomics
  56. 7.10.1 Berry Genomics Company Information
  57. 7.10.2 Berry Genomics Business Overview
  58. 7.10.3 Berry Genomics Non-Invasive Prenatal Screening (NIPS) Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Berry Genomics Non-Invasive Prenatal Screening (NIPS) Product Portfolio
  60. 7.10.5 Berry Genomics Recent Developments
  61. 7.11 Annaroad
  62. 7.11.1 Annaroad Company Information
  63. 7.11.2 Annaroad Business Overview
  64. 7.11.3 Annaroad Non-Invasive Prenatal Screening (NIPS) Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Annaroad Non-Invasive Prenatal Screening (NIPS) Product Portfolio
  66. 7.11.5 Annaroad Recent Developments
  67. 7.12 Genesky
  68. 7.12.1 Genesky Company Information
  69. 7.12.2 Genesky Business Overview
  70. 7.12.3 Genesky Non-Invasive Prenatal Screening (NIPS) Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Genesky Non-Invasive Prenatal Screening (NIPS) Product Portfolio
  72. 7.12.5 Genesky Recent Developments
  73. 7.13 Weihansi Biomedical Technology
  74. 7.13.1 Weihansi Biomedical Technology Company Information
  75. 7.13.2 Weihansi Biomedical Technology Business Overview
  76. 7.13.3 Weihansi Biomedical Technology Non-Invasive Prenatal Screening (NIPS) Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Weihansi Biomedical Technology Non-Invasive Prenatal Screening (NIPS) Product Portfolio
  78. 7.13.5 Weihansi Biomedical Technology Recent Developments
8 North America
  1. 8.1 North America Non-Invasive Prenatal Screening (NIPS) Revenue (2021-2032)
  2. 8.2 North America Non-Invasive Prenatal Screening (NIPS) Revenue by Type (2021-2032)
  3. 8.2.1 North America Non-Invasive Prenatal Screening (NIPS) Revenue by Type (2021-2026)
  4. 8.2.2 North America Non-Invasive Prenatal Screening (NIPS) Revenue by Type (2027-2032)
  5. 8.3 North America Non-Invasive Prenatal Screening (NIPS) Revenue Share by Type (2021-2032)
  6. 8.4 North America Non-Invasive Prenatal Screening (NIPS) Revenue by Application (2021-2032)
  7. 8.4.1 North America Non-Invasive Prenatal Screening (NIPS) Revenue by Application (2021-2026)
  8. 8.4.2 North America Non-Invasive Prenatal Screening (NIPS) Revenue by Application (2027-2032)
  9. 8.5 North America Non-Invasive Prenatal Screening (NIPS) Revenue Share by Application (2021-2032)
  10. 8.6 North America Non-Invasive Prenatal Screening (NIPS) Revenue by Country
  11. 8.6.1 North America Non-Invasive Prenatal Screening (NIPS) Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Non-Invasive Prenatal Screening (NIPS) Revenue by Country (2021-2026)
  13. 8.6.3 North America Non-Invasive Prenatal Screening (NIPS) Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Non-Invasive Prenatal Screening (NIPS) Revenue (2021-2032)
  2. 9.2 Europe Non-Invasive Prenatal Screening (NIPS) Revenue by Type (2021-2032)
  3. 9.2.1 Europe Non-Invasive Prenatal Screening (NIPS) Revenue by Type (2021-2026)
  4. 9.2.2 Europe Non-Invasive Prenatal Screening (NIPS) Revenue by Type (2027-2032)
  5. 9.3 Europe Non-Invasive Prenatal Screening (NIPS) Revenue Share by Type (2021-2032)
  6. 9.4 Europe Non-Invasive Prenatal Screening (NIPS) Revenue by Application (2021-2032)
  7. 9.4.1 Europe Non-Invasive Prenatal Screening (NIPS) Revenue by Application (2021-2026)
  8. 9.4.2 Europe Non-Invasive Prenatal Screening (NIPS) Revenue by Application (2027-2032)
  9. 9.5 Europe Non-Invasive Prenatal Screening (NIPS) Revenue Share by Application (2021-2032)
  10. 9.6 Europe Non-Invasive Prenatal Screening (NIPS) Revenue by Country
  11. 9.6.1 Europe Non-Invasive Prenatal Screening (NIPS) Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Non-Invasive Prenatal Screening (NIPS) Revenue by Country (2021-2026)
  13. 9.6.3 Europe Non-Invasive Prenatal Screening (NIPS) Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Non-Invasive Prenatal Screening (NIPS) Revenue (2021-2032)
  2. 10.2 China Non-Invasive Prenatal Screening (NIPS) Revenue by Type (2021-2032)
  3. 10.2.1 China Non-Invasive Prenatal Screening (NIPS) Revenue by Type (2021-2026)
  4. 10.2.2 China Non-Invasive Prenatal Screening (NIPS) Revenue by Type (2027-2032)
  5. 10.3 China Non-Invasive Prenatal Screening (NIPS) Revenue Share by Type (2021-2032)
  6. 10.4 China Non-Invasive Prenatal Screening (NIPS) Revenue by Application (2021-2032)
  7. 10.4.1 China Non-Invasive Prenatal Screening (NIPS) Revenue by Application (2021-2026)
  8. 10.4.2 China Non-Invasive Prenatal Screening (NIPS) Revenue by Application (2027-2032)
  9. 10.5 China Non-Invasive Prenatal Screening (NIPS) Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Non-Invasive Prenatal Screening (NIPS) Revenue (2021-2032)
  2. 11.2 Asia Non-Invasive Prenatal Screening (NIPS) Revenue by Type (2021-2032)
  3. 11.2.1 Asia Non-Invasive Prenatal Screening (NIPS) Revenue by Type (2021-2026)
  4. 11.2.2 Asia Non-Invasive Prenatal Screening (NIPS) Revenue by Type (2027-2032)
  5. 11.3 Asia Non-Invasive Prenatal Screening (NIPS) Revenue Share by Type (2021-2032)
  6. 11.4 Asia Non-Invasive Prenatal Screening (NIPS) Revenue by Application (2021-2032)
  7. 11.4.1 Asia Non-Invasive Prenatal Screening (NIPS) Revenue by Application (2021-2026)
  8. 11.4.2 Asia Non-Invasive Prenatal Screening (NIPS) Revenue by Application (2027-2032)
  9. 11.5 Asia Non-Invasive Prenatal Screening (NIPS) Revenue Share by Application (2021-2032)
  10. 11.6 Asia Non-Invasive Prenatal Screening (NIPS) Revenue by Country
  11. 11.6.1 Asia Non-Invasive Prenatal Screening (NIPS) Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Non-Invasive Prenatal Screening (NIPS) Revenue by Country (2021-2026)
  13. 11.6.3 Asia Non-Invasive Prenatal Screening (NIPS) Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Non-Invasive Prenatal Screening (NIPS) Revenue (2021-2032)
  2. 12.2 SAMEA Non-Invasive Prenatal Screening (NIPS) Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Non-Invasive Prenatal Screening (NIPS) Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Non-Invasive Prenatal Screening (NIPS) Revenue by Type (2027-2032)
  5. 12.3 SAMEA Non-Invasive Prenatal Screening (NIPS) Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Non-Invasive Prenatal Screening (NIPS) Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Non-Invasive Prenatal Screening (NIPS) Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Non-Invasive Prenatal Screening (NIPS) Revenue by Application (2027-2032)
  9. 12.5 SAMEA Non-Invasive Prenatal Screening (NIPS) Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Non-Invasive Prenatal Screening (NIPS) Revenue by Country
  11. 12.6.1 SAMEA Non-Invasive Prenatal Screening (NIPS) Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Non-Invasive Prenatal Screening (NIPS) Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Non-Invasive Prenatal Screening (NIPS) Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst